GENE - Genetic Technologies secures new U.S. patent for genetype COVID-19 Risk Test

Genetic Technologies (NASDAQ:GENE) confirms that its U.S. patent application for novel geneType COVID-19 Risk Test has been accepted. GENE shares up 3.6% premarket at $2.33. Formalities will be reviewed and a formal report will be provided within next 10 days which will include the patent number. The Company also announced a new partnership to expand access to the COVID-19 Risk Test in the U.S. through agreement with IBX and 1health. Cross validation of the geneType COVID-19 Risk Test completed in an independent cohort confirms test performance.

For further details see:

Genetic Technologies secures new U.S. patent for genetype COVID-19 Risk Test